Magnolol / HDAC Cancer Research Results

MAG, Magnolol: Click to Expand ⟱

Features:

Lignan found in bark of some magnolia species.
Magnolol (MAG) — a bioactive biphenolic compound from Magnolia officinalis
derived from the bark (roots and branches) of Magnolia species such as M. officinalis, M. obovata, and M. grandiflora
The two main bioactive compounds isolated from these plants are MAG (5,5ʹ-diallyl-2,2ʹ-dihydroxybiphenyl) and Honokiol (3,5ʹ-diallyl-4,2ʹ-dihydroxybiphenyl) (Fig. 1) which are phenolic regioisomers.
In the bark extracts of Magnolia plants, the composition of MAG ranges from 1 to 10%, while Honokiol comprises 1 to 5%
Magnolol is a biphenolic neolignan isolated from the bark of Magnolia officinalis. It is structurally related to honokiol and is studied for anti-inflammatory, antioxidant, antimicrobial, and neuroactive effects. In preclinical oncology models, magnolol is reported to modulate NF-κB, STAT3, PI3K/AKT, MAPK, Wnt/β-catenin, and redox pathways, with downstream effects on cell-cycle arrest, apoptosis, invasion/EMT, and angiogenesis. Oral bioavailability is limited and many cytotoxic concentrations reported in vitro are in the tens of µM range, often above typical systemic levels from standard supplementation.

major pathways and molecular targets involved in magnolol’s anticancer actions:
-Apoptosis: ↑ Bax, ↓ Bcl-2, ↑ cytochrome c, ↑ caspase-9, ↑ caspase-3
-Arrests cell cycle at G0/G1 or G2/M phase:↓ Cyclin D1, CDK4, CDK6, Cyclin B1, CDK1
-Inhibits NF-κB activation: ↓ IκBα, COX-2, TNF-α
-Inhibits PI3K, Akt, and mTOR phosphorylation
-Suppresses angiogenesis: ↓ Bcl-XL, Mcl-1, VEGF, cyclin D1
-Inhibits β-catenin nuclear translocation
-increase ROS production in tumor cells → triggers mitochondrial apoptosis
-Magnolol activates Nrf2 in normal cells → upregulates HO-1, NQO1: Protects normal tissue from oxidative stress during chemotherapy or inflammation.

Most in-vitro IC50 values fall in the 10–100 µM range, often above typical systemic exposure.

Rank	Pathway / Axis	Cancer / Tumor Context	Normal Tissue Context	TSF	Primary Effect	Notes / Interpretation
1	NF-κB inflammatory / survival transcription	NF-κB ↓; COX-2, cytokines, Bcl-2 family ↓ (reported)	Inflammation tone ↓	R, G	Anti-inflammatory + anti-survival transcription	One of the most consistently reported mechanisms in both inflammatory and tumor models.
2	STAT3 signaling	STAT3 phosphorylation ↓ (reported)	↔	R, G	Oncogenic transcription suppression	Reported in several cancer cell systems; contributes to reduced proliferation and survival signaling.
3	PI3K → AKT → mTOR pathway	PI3K/AKT signaling ↓ (model-dependent)	↔	R, G	Growth/survival modulation	Frequently described as downstream of inflammatory pathway suppression; context-dependent strength.
4	Nrf2 / ARE antioxidant response	Modulation context-dependent; may decrease oxidative stress or alter redox tone	Nrf2 ↑; HO-1 ↑; GSH ↑ (cytoprotective)	R, G	Redox regulation	Magnolol activates Nrf2 in non-malignant oxidative stress models; tumor direction varies and may influence therapy sensitivity.
5	MAPK pathways (ERK / JNK / p38)	MAPK modulation (stress activation or ERK suppression; context-dependent)	↔	P, R, G	Signal reprogramming	JNK/p38 activation and ERK modulation reported variably depending on cell type and dose.
6	Cell-cycle arrest (G0/G1 or G2/M)	Cell-cycle arrest ↑ (reported)	↔	G	Cytostasis	Associated with Cyclin D1/CDK modulation and checkpoint protein regulation.
7	Intrinsic apoptosis (mitochondrial pathway)	Apoptosis ↑; caspases ↑; Bax/Bcl-2 ratio ↑ (reported)	↔ (generally less activation)	G	Cell death execution	Often downstream of survival pathway inhibition and ROS signaling shifts.
8	ROS / redox modulation	ROS ↑ in some tumor models; antioxidant effects in non-tumor systems	Oxidative stress ↓ in inflammatory models	P, R, G	Context-dependent redox modulation	Biphasic redox behavior similar to other polyphenols; not a universally tumor-selective pro-oxidant.
9	Wnt/β-catenin signaling	β-catenin signaling ↓ (reported)	↔	G	Proliferation/invasion modulation	Reported particularly in colorectal and hepatocellular carcinoma models; keep model-qualified.
10	Invasion / metastasis (MMPs / EMT)	MMP2/MMP9 ↓; EMT markers ↓; migration ↓ (reported)	↔	G	Anti-invasive phenotype	Often secondary to NF-κB/STAT3 pathway suppression.
11	Bioavailability constraint	Limited oral bioavailability; rapid metabolism	—	—	Translation constraint	Plasma levels after oral dosing are typically lower than many in-vitro cytotoxic concentrations.

Time-Scale Flag (TSF): P / R / G

P: 0–30 min (rapid signaling/redox interactions)
R: 30 min–3 hr (acute transcription and stress-response signaling shifts)
G: >3 hr (gene-regulatory adaptation and phenotype outcomes)

HDAC, Histone deacetylases: Click to Expand ⟱

Source:

Type:

Enzymes involved in regulating gene expression by removing acetyl groups from histones, the proteins around which DNA is wrapped.
-Many cancers exhibit altered expression levels of HDACs, which can contribute to the dysregulation of genes involved in cell growth, survival, and differentiation.
-HDACs can repress the expression of tumor suppressor genes, leading to uncontrolled cell proliferation and survival. This repression can be a key factor in the development and progression of cancer.
-HDAC inhibitors (HDACi) have been developed and are being investigated for their ability to reactivate silenced genes, induce cell cycle arrest, and promote apoptosis in cancer cells.
-HDAC1, HDAC2): Often overexpressed in various cancers, including breast, prostate, and colorectal cancers. Their overexpression is associated with poor prognosis.
-HDAC4, HDAC5): These may have both oncogenic and tumor-suppressive roles depending on the context and cancer type.
-While HDACs are not classified as traditional oncogenes, their overexpression and activity can contribute to oncogenic processes.
-HDAC inhibitor works by preventing the removal of acetyl groups from histones, thereby modulating gene expression, influencing cell behavior, and potentially reversing aberrant gene silencing seen in various diseases.
-HDAC inhibitors can help reactivate these genes, thereby inhibiting growth and inducing apoptosis in cancer cells.

Scientific Papers found: Click to Expand⟱

1196-

MAG,

2-O-Methylmagnolol, a Magnolol Derivative, Suppresses Hepatocellular Carcinoma Progression via Inhibiting Class I Histone Deacetylase Expression

in-vitro,

HCC,

TumCG↓, TumCMig↓, TumCI↓, TumCCA↑, HDAC↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:

Cell Cycle & Senescence ⓘ

TumCCA↑, 1,

Proliferation, Differentiation & Cell State ⓘ

HDAC↓, 1, TumCG↓, 1,

Migration ⓘ

TumCI↓, 1, TumCMig↓, 1,
Total Targets: 5

Pathway results for Effect on Normal Cells:

Total Targets: 0

Scientific Paper Hit Count for: HDAC, Histone deacetylases

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells